Clinical Trial Update: A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study evaluated how normal, moderate, and severe hepatic impairment affects exposure to velpatasvir (GS-5816) in adults with Chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Velpatasvir (velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 1 | Status: COMPLETED